- Home
- GH vs FSK Comparison
GH vs FSK Comparison
Compare GH & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- FSK
- Stock Information
- Founded
- GH 2011
- FSK 2007
- Country
- GH United States
- FSK United States
- Employees
- GH N/A
- FSK N/A
- Industry
- GH Medical Specialities
- FSK Investment Managers
- Sector
- GH Health Care
- FSK Finance
- Exchange
- GH Nasdaq
- FSK Nasdaq
- Market Cap
- GH 6.1B
- FSK 6.0B
- IPO Year
- GH 2018
- FSK N/A
- Fundamental
- Price
- GH $40.64
- FSK $20.96
- Analyst Decision
- GH Strong Buy
- FSK Hold
- Analyst Count
- GH 20
- FSK 8
- Target Price
- GH $48.40
- FSK $21.06
- AVG Volume (30 Days)
- GH 2.6M
- FSK 1.8M
- Earning Date
- GH 05-08-2025
- FSK 05-07-2025
- Dividend Yield
- GH N/A
- FSK 13.37%
- EPS Growth
- GH N/A
- FSK N/A
- EPS
- GH N/A
- FSK 2.09
- Revenue
- GH $739,016,000.00
- FSK $1,721,000,000.00
- Revenue This Year
- GH $19.11
- FSK N/A
- Revenue Next Year
- GH $21.44
- FSK N/A
- P/E Ratio
- GH N/A
- FSK $10.03
- Revenue Growth
- GH 31.04
- FSK N/A
- 52 Week Low
- GH $15.81
- FSK $18.31
- 52 Week High
- GH $50.89
- FSK $24.10
- Technical
- Relative Strength Index (RSI)
- GH 46.62
- FSK 29.94
- Support Level
- GH $34.88
- FSK $22.18
- Resistance Level
- GH $45.00
- FSK $22.95
- Average True Range (ATR)
- GH 3.11
- FSK 0.63
- MACD
- GH -0.28
- FSK -0.26
- Stochastic Oscillator
- GH 51.89
- FSK 2.04
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About FSK FS KKR Capital Corp.
FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.